Patients experiencing symptoms such as chest pain who received from paramedics an intravenous solution consisting of glucose-insulin-potassium (GIK) had no reduction in the rate of progression to heart attack and no improvement ...
Mar 27, 2012
0
0
Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events, according to a research letter published online May 30 in JAMA Network Open.
Jun 3, 2024
0
4
That feeling of crushing pain in your chest can be a medical emergency, but it can also be angina pectoris, or "stable angina"—a symptom of coronary heart disease that can be managed with medication.
Feb 7, 2023
0
5
Generic anti-platelet drugs seem to work as well as a brand name drug for heart patients, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
Mar 13, 2018
0
23
Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events (MACE) ...
Mar 12, 2018
0
5
The absolute cumulative probability of death at 12 months was 5 percent lower for patients who received routine invasive coronary angiography and revascularization as indicated during an unstable angina admission compared ...
May 1, 2017
0
0
Patients with acute coronary syndrome who were treated with the blood-thinning drug rivaroxaban in addition to an antiplatelet medication (clopidogrel or ticagrelor) experienced no increase in bleeding complications compared ...
Mar 20, 2017
0
0
Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol ...
Apr 4, 2016
0
1
(HealthDay)—The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according ...
Dec 3, 2015
0
0
Ezetimibe reduces cardiovascular events in patients with diabetes and a recent acute coronary syndrome, according to a subgroup analysis of the IMPROVE-IT trial presented at ESC Congress today by co-principal investigator ...
Aug 30, 2015
0
7
